Business Description
Antibe Therapeutics Inc
NAICS : 541714
SIC : 3741
ISIN : CA0370251039
Compare
Compare
Traded in other countries / regions
ATE.CanadaATBPF.USA4B70.Germany IPO Date
2014-08-13Description
Antibe Therapeutics Inc is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The company's pipeline includes assets that seek to overcome gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs. Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for post-operative pain. Antibe's second pipeline drug, ATB-352, is being developed for a specialized acute pain indication. The company's anticipated next target is inflammatory bowel disease, a condition long in need of safer, more effective therapies.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.46 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 17.6 | |||||
| 3-Year EPS without NRI Growth Rate | 17.9 | |||||
| 3-Year FCF Growth Rate | 9.1 | |||||
| 3-Year Book Growth Rate | 80.8 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 46.67 | |||||
| 9-Day RSI | 38.9 | |||||
| 14-Day RSI | 35.2 | |||||
| 6-1 Month Momentum % | -5.79 | |||||
| 12-1 Month Momentum % | -19.42 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 10.06 | |||||
| Quick Ratio | 10.06 | |||||
| Cash Ratio | 8.91 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -21.5 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -53.35 | |||||
| ROA % | -28.31 | |||||
| ROIC % | -68.45 | |||||
| ROC (Joel Greenblatt) % | -1933.62 | |||||
| ROCE % | -29.22 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.6 | |||||
| EV-to-EBIT | 2.15 | |||||
| EV-to-EBITDA | 2.15 | |||||
| EV-to-FCF | 2.15 | |||||
| Earnings Yield (Greenblatt) % | 46.51 | |||||
| FCF Yield % | -116.67 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:ATBPF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Antibe Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.261 | ||
| Beta | 0.04 | ||
| Volatility % | 74.7 | ||
| 14-Day RSI | 35.2 | ||
| 14-Day ATR ($) | 0.024767 | ||
| 20-Day SMA ($) | 0.234747 | ||
| 12-1 Month Momentum % | -19.42 | ||
| 52-Week Range ($) | 0.1113 - 0.8855 | ||
| Shares Outstanding (Mil) | 53.01 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Antibe Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Antibe Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Antibe Therapeutics Inc Frequently Asked Questions
What is Antibe Therapeutics Inc(ATBPF)'s stock price today?
The current price of ATBPF is $0.22. The 52 week high of ATBPF is $0.89 and 52 week low is $0.11.
When is next earnings date of Antibe Therapeutics Inc(ATBPF)?
The next earnings date of Antibe Therapeutics Inc(ATBPF) is .
Does Antibe Therapeutics Inc(ATBPF) pay dividends? If so, how much?
Antibe Therapeutics Inc(ATBPF) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers